The Israeli Phage Therapy Center (IPTC), led by two Hebrew University of Jerusalem professors, has used a bacteriophage PASA16 on compassionate basis to treat tough Pseudomonas aeruginosa infections in 16 patients. It has shown promising results with an 86.6% success … Continue reading →

Israel’s Mileutis (see here previously) is “bullish” about its Imilac peptide alternative to antibiotics in dairy cows. Imilac boosts the immune system to fight infections and doesn’t increase antibiotic resistance. The cows also produce more milk. Mileutis says the same … Continue reading →

The Hebrew University of Jerusalem and Israel’s Tissue Dynamics again used their “sensors on a chip” to bypass animal testing in developing a new treatment. They proved that the diabetic drug empagliflozin blocks the toxicity of aminoglycoside antibiotics in kidney … Continue reading →

Researchers from Israel’s Ben-Gurion University have discovered that the phytochemical 3,3′-diindolylmethane (DIM) kills bacteria and heals wounds fast. DIM is derived from cruciferous vegetables such as broccoli. The BGU spinoff startup Lifematters is further developing DIM. https://www.jpost.com/health-and-wellness/article-711688 https://www.mdpi.com/1999-4923/14/5/967 https://www.timesofisrael.com/israeli-study-chemical-heals-wounds-twice-as-fast-could-be-antibiotic-alternative/ http://lifematters.co.il/

An AI tool from Israel’s Technion Institute helps combat antibiotic resistance. It reduced ineffective antibiotics prescribed for urinary tract infections by 35%. The tool was trialed by Israel’s Maccabi Health Management Organization (HMO) and will now be used for other … Continue reading →

Researchers from the Hebrew University of Jerusalem have discovered that some bacteria enter a “disrupted” state when attacked but not destroyed by antibiotics. A different chemical is then needed to “finish them off”, otherwise they can eventually recover and reproduce. … Continue reading →

Tel Aviv University researchers have developed a biological antibiotic derived from human monoclonal antibodies, as an alternative to traditional chemical antibiotics. The antibodies were taken from a recovered tuberculosis patient and were shown to kill TB bacteria – still a … Continue reading →

Israel’s Omnix (reported here previously) has been awarded €10.8 million in EU funding under the EIC Accelerator Programme, part of the EU’s Horizon 2020 research funding program. Omnix’s OMN6 peptide destroys the bacteria’s membrane, regardless of its resistance. https://www.calcalistech.com/ctech/articles/0,7340,L-3889749,00.html https://www.omnixmedical.com/omnix-medical-wins-e10-8m-in-eic-accelerator-funding/

Israel’s Omnix Medical (reported here previously( is developing novel antibiotic agents for the treatment of hospital-acquired infections involving resistant bacteria. Omnix has successfully completed lab testing and has now raised funding to allow it to commence human clinical trials. https://www.calcalistech.com/ctech/articles/0,7340,L-3868294,00.html … Continue reading →

Israeli biotech Mileutis has developed Imilac – designed to treat mastitis in cows by boosting their immune systems. Imilac is near the marketing stage and can replace the wide use of antibiotics for which resistance is growing and being passed … Continue reading →